Clinical trials: Biliary Cancers
Esophageal Cancer, Gastric Cancer
T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive System
This phase I trial is to investigate the safety and the possible side effects of bi-specific antibody armed T-cell therapy when given together with low-dose IL-2 in treating patients with Her2-positive neoplasms of digestive…
- Conditions
- Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Liver Cancer
- Trial name
- NCT02662348
- Testing
- Recombinant Human Interleukin-2, HER2Bi-Armed T Cells
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Yi Miao
Biliary Tract Cancer, Extrahepatic Cholangiocarcinoma
Adjuvant Immunotherapy Combined With Chemoradiation for Patients With High-risk reseCtable Extrahepatic chOlangiocaRcinoma and gallblaDder Cancer
The study is a multicenter phase II randomized controlled trial. The purpose is to investigate the efficacy and safety of adjuvant immunotherapy combined with chemoradiation for patients with high-risk resectable extrahepatic…
- Conditions
- Biliary Tract Cancer, Extrahepatic Cholangiocarcinoma, Gallbladder Cancer
- Trial name
- ACCORD (NCT04333927)
- Testing
- Chemotherapy, Observation, Immunotherapy
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Sun Yat-sen University
Ampulla of Vater Adenocarcinoma, Gallbladder Adenocarcinoma
ADH-1, Gemcitabine Hydrochloride & Cisplatin in Treating Metastatic Pancreatic or Biliary Tract Cancer
This phase I trial studies the side effects and best dose of ADH-1 when given together with gemcitabine hydrochloride and cisplatin in treating patients with pancreatic or biliary tract cancer that has spread from where it…
- Conditions
- Ampulla of Vater Adenocarcinoma, Gallbladder Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT01825603
- Testing
- ADH-1, Cisplatin, Gemcitabine Hydrochloride
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Nebraska
Radiation Therapy, Cancer
Radiotherapy Assessments During Intervention ANd Treatment (RADIANT)
Collect blood samples and associated clinical data prior to, during, and post radiation treatment.
- Conditions
- Radiation Therapy, Cancer, Cancer of Anus, Cancer of Bladder
- Trial name
- RADIANT (NCT03133286)
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- DxTerity Diagnostics
Pancreatic Cancer, Bile Duct Cancer
Randomized Controlled Trial on Pancreatic Stent Tube in Pancreaticoduodenectomy
The purpose of this study is to determine which stent type is effective in the decrease of postoperative stay and complications across pancreaticojejunostomy after pancreaticoduodenectomy.
- Conditions
- Pancreatic Cancer, Bile Duct Cancer, Ampullary Cancer, Pancreatitis
- Trial name
- NCT00628186
- Testing
- external drainage tube [polyethylene pancreatic drainage tube], internal drainage tube [polyethylene pancreatic drainage tube]
- Where
- Japan
- Volunteers
- 100 people
- Sponsor
- Wakayama Medical University
Biliary Tract Diseases, Gallbladder Cancer
Construction of Multicenter Retrospective Registry Cohort Database for Gallbladder Cancer
The aim of the study is to establishing a standardized clinical information database for patients with malignant tumors of gallbaldder.
- Conditions
- Biliary Tract Diseases, Gallbladder Cancer, Gallbladder Neoplasms
- Trial name
- CRGGCext (NCT06276153)
- Testing
- no interventions
- Volunteers
- 5,000 people
- Sponsor
- RenJi Hospital
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Gemcitabine and Capecitabine in Treating Patients With Advanced and/or Inoperable Cholangiocarcinoma or Carcinoma of the Gallbladder
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00084942
- Testing
- capecitabine, gemcitabine hydrochloride
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer
RATIONALE: Drugs used in chemotherapy such as gemcitabine work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
- Trial name
- NCT00059865
- Testing
- gemcitabine hydrochloride, pemetrexed disodium
- Where
- 41 sites in United States
- Volunteers
- 68 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Cholangiocarcinoma, Biliary Stricture
Diagnostic Accuracy of ERCP-guided Versus Cholangioscopy-guided Tissue Acquisition in Patients With Indeterminate Biliary Strictures Suspected to be Intrinsic .
Primary Objective: To assess the diagnostic accuracy of cholangioscopy-based assessment using SpyDS technology compared to cholangiography-based assessment using ERCP-guided biopsy and brushing in patients with indeterminate…
- Trial name
- Cholangioscopy (NCT03140007)
- Testing
- single operator cholangioscopy, ERCP guided brushing and biopsy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Asian Institute of Gastroenterology, India
Pancreatic Head Cancer, Obstructive Jaundice
Endoscopic Versus Percutaneous Biliary Drainage for Resectable Pancreatic Head Cancer
Patients with potentially resectable pancreatic head cancer and high bilirubin level, were stratified into two equal groups according to the method of biliary drainage: endoscopic stenting or percutaneous drainage.
- Trial name
- NCT04823832
- Testing
- pancreaticoduodenectomy
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Hani Alhadad
Biliary Tract Cancer
Trial of Infusional FOLFIRINOX in First Line Treatment of Advanced Biliary Tract Cancers
This study is to evaluate the response rate and toxicity profile of infusional 5 fluorouracil, leucovorin, oxaliplatin and irinotecan (FOLFIRINOX) in first-line treatment of advanced biliary tract cancers and also to assess…
- Trial name
- FBI-TRAC (NCT03291899)
- Testing
- FOLFIRINOX
- Where
- Saudi Arabia
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- King Faisal Specialist Hospital & Research Center
Biliary Tract Cancer
A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer
This study will evaluate the efficacy and safety of atezolizumab with bevacizumab in combination with cisplatin and gemcitabine(CisGem), compared with atezolizumab in combination with CisGem, in participants with advanced biliary…
- Trial name
- NCT04677504
- Testing
- Atezolizumab, Bevacizumab, Cisplatin
- Where
- 49 sites in United States, China and 11 more
- Volunteers
- 162 people
- Sponsor
- Hoffmann-La Roche
Metastatic Biliary Tract Carcinoma
A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy
Based on the facts of multiple pathways involvement in cholangiocarcinoma tumor genesis, including EGFR, Ras, Raf, VEGFR, and PDGFR, with evidence of overexpression of these proteins associated with tumor stage, prognosis and…
- Trial name
- NCT02053376
- Testing
- Regorafenib
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Nathan Bahary, MD
Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
This phase II ComboMATCH treatment trial compares the usual treatment of modified leucovorin, fluorouracil and oxaliplatin (mFOLFOX6) chemotherapy to using binimetinib plus mFOLFOX6 chemotherapy to shrink tumors in patients with…
- Conditions
- Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma, Advanced Intrahepatic Cholangiocarcinoma, Recurrent Biliary Tract Carcinoma
- Trial name
- NCT05564403
- Testing
- Binimetinib, Biopsy Procedure, Biospecimen Collection
- Where
- 207 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Bile Duct Neoplasms, Colorectal Neoplasms
Codman Catheter/Synchromed Pump Hepatic Artery Chemotherapy for Unresectable Colorectal Metastases/Intrahepatic Cholangiocarcinoma
Due to discontinuation of the Codman C3000 pump, an alternate device is necessary to continue serving patients in need of hepatic arterial infusion chemotherapy.
- Trial name
- NCT04276090
- Testing
- Hepatic artery infusion pump placement using the Synchromed II pump and the Codman tapered arterial catheter., Hepatic artery infusion pump floxuridine and dexamethasone, Systemic chemotherapy for colorectal liver metastases
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Michael J Cavnar, MD
Biliary Tract Cancer
ctDNA Detection of MRD in Predicting Postoperative Recurrence in Biliary Tract Cancers：A Multicenter Prospective Trial
A substantial proporation of patients with biliary tract malignancies still experience disease recurrence after curative resection.
- Trial name
- NCT05743959
- Testing
- No intervention
- Where
- China
- Volunteers
- 100 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Congenital Biliary Dilatation, Choledochal Cyst
The Application of Digital Intelligent Diagnostic and Therapeutic Technology in Biliary Dilation Diagnosis
This research discusses the clinical application value of augmented reality navigation technology combined with three-dimensional visualization technology in improving surgical safety and promoting the development of precision…
- Trial name
- DIIBD (NCT06418490)
- Testing
- Three-dimensional visualization technology
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhujiang Hospital
Cholangiocarcinoma, Pancreatic Adenocarcinoma
FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers
Pancreatic cancer is one of the worst-prognosed cancers with a 5-year survival rate of less than 10%. Its incidence has been steadily increasing for several years in France and worldwide.
- Trial name
- FAPDIG (NCT07478523)
- Testing
- TEP-TDM au 68Ga-FAPI-46
- Where
- France
- Volunteers
- 120 people
- Sponsor
- University Hospital, Bordeaux
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Biliary Tract Cancer
Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tract Cancer
To evaluate the efficacy and safety of Anlotinib Hydrochloride in Combination With PD1 With Gemcitabine Plus(+)Cisplatin Compared With Gemcitabine +Cisplatin as First-line Chemotherapy for Unresectable or Metastatic Biliary Tract…
- Trial name
- NCT04300959
- Testing
- Anlotinib Hydrochloride in Combination With PD1 With Gemcitabine Plus(+)Cisplatin, Gemcitabine Plus(+)Cisplatin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Zhejiang Cancer Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.